Abstract
The AIDS pandemic has already taken the lives of over 25 million people since 1981 and there are over 40 million people living with HIV. The replication of this virus depends on the unique production of a DNA copy of its genome from a single-stranded RNA template. This phenomenon has two critical outcomes: it creates a target for effective antiretroviral drugs and generates an ever-increasing number of genetic variants of the virus that leads to drug-resistant strains. The molecular basis for drug resistance stems from mutations in viral enzymes, each mutation corresponding to the acquisition of resistance to different sets of drugs. Thus genotypic testing, determining the mutation profile of a patient's HIV, can provide insight to the clinician as to how to design a most effective cocktail of drugs for that patient. The basis and the power of genotypic testing in HIV therapy is presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Healthcare Technology and Management
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
